Core Viewpoint - The announcement highlights that CSPC Pharmaceutical Group has received drug registration approval from the National Medical Products Administration of China for its Lercanidipine injection, which is a rapid-acting intravenous antihypertensive medication designed for patients who cannot take oral medications effectively [1] Group 1: Product Details - The Lercanidipine injection is classified as a dihydropyridine calcium channel blocker and is intended for the treatment of hypertension [1] - The product is available in two formulations: 25mg in a 50ml vial and 50mg in a 100ml vial [1] Group 2: Advantages - The product offers significant advantages over commonly used medications, including faster onset of action and the ability to achieve rapid, real-time, and precise blood pressure control [1] - It is particularly suitable for patients with liver and kidney dysfunction, as dosage adjustments are not required during treatment [1] - The formulation does not require dilution, which can significantly benefit patients at risk of fluid overload [1] Group 3: Market Impact - The approval of this product will enhance CSPC's product pipeline in the cardiovascular disease treatment sector, increasing its competitiveness in this field [1] - The product is expected to address the clinical demand gap for emergency hypertension medications [1]
石药集团：氯维地平乳状注射液获药品注册批件